日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. CD79B (US20210261659A1 Biosimilar) Recombinant Monoclonal Antibody

CD79B (US20210261659A1 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA004958MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CD79B (US20210261659A1 Biosimilar Antibody) 重組單克隆抗體是一種針對人CD79B分子，其來源于重組人CD79B蛋白，具有高度的人源種屬反應性。CD79B作為B細胞抗原受體復合物相關蛋白β鏈，又名B29、Ig-β或IGB等，在B細胞發(fā)育、活化及信號傳導中發(fā)揮關鍵作用，其異常表達與B細胞惡性腫瘤密切相關。 US20210261659A1 Biosimilar主要用于B細胞淋巴瘤（如彌漫大B細胞淋巴瘤、濾泡性淋巴瘤）的靶向治療。通過特異性結(jié)合CD79B，可誘導抗體依賴的細胞毒性作用（ADCC）和補體依賴的細胞毒性作用（CDC），精準清除腫瘤細胞。相關研究顯示，其與化療藥物或其他靶向藥物聯(lián)合使用，能顯著提高患者緩解率，延長無進展生存期，尤其為復發(fā)/難治性病例提供了新治療選擇。目前，針對該抗體研發(fā)的藥物的臨床試驗重點關注其有效性、安全性及與原研藥的一致性，以推動其在臨床的廣泛應用。 CD79B抗體是B細胞生物學研究的重要工具。它可用于檢測B細胞表面CD79B的表達水平，分析其在組織切片中的定位，以及免疫沉淀和實驗，探究CD79B在B細胞受體信號通路中的分子機制。此外，該抗體還可用于構建CD79B靶向的基因編輯或動物模型，助力研究B細胞相關疾病的發(fā)病機制及新藥篩選，為淋巴瘤等疾病的基礎研究與轉(zhuǎn)化醫(yī)學提供關鍵支持。
  • Uniprot No.：
  • 基因名：
  • 別名：
    AGM6 antibody; B cell antigen receptor complex associated protein beta chain antibody; B cell specific glycoprotein B29 antibody; B-cell antigen receptor complex-associated protein beta chain antibody; B-cell-specific glycoprotein B29 antibody; B29 antibody; B29/Ig-beta/CD79b antibody; CD 79b antibody; CD79b antibody; CD79b antigen；immunoglobulin associated beta antibody; CD79b antigen antibody; CD79b molecule antibody; CD79b molecule immunoglobulin associated beta antibody; CD79b protein antibody; CD79B_HUMAN antibody; Ig beta antibody; Ig-beta antibody; IGB antibody; Igbeta antibody; Immunoglobulin associated B29 antibody; Immunoglobulin associated B29 protein antibody; Immunoglobulin associated beta antibody; Immunoglobulin associated protein antibody; Immunoglobulin-associated B29 protein antibody; MGC108607 antibody
  • 反應種屬：
    Human
  • 免疫原：
    Recombinant Human CD79B protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
  • 基因功能參考文獻：
    1. CD79B mutations were found in six of 19 cases (31.6%) of primary CNS diffuse large B-cell lymphoma , all in the Y196 mutation hotspot PMID: 28856744
    2. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of CD79B mutations. PMID: 28803429
    3. hotspot mutations of CD79B Y196 and MYD88 L265 may serve as a genetic hallmark for primary central nervous system lymphoma PMID: 26111727
    4. CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib. PMID: 26699656
    5. Novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients were detected. PMID: 27010137
    6. MYD88 L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma. PMID: 26752547
    7. Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system. PMID: 25347427
    8. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. PMID: 25501023
    9. Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies. PMID: 25414443
    10. results suggest that MYD88 mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL PMID: 24253023
    11. CD79B and MYD88 mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease. PMID: 24444466
    12. CD79B point mutation is associated with B-cell non-Hodgkin lymphomas. PMID: 23361872
    13. Data indicate a secondary promoter located within exon 2 maintained full levels and specificity of hCD79b transcription. PMID: 23649625
    14. The present study failed to find any mut-ation in MYD88, CARD11 or CD79B in ocular MALT lymphoma. PMID: 22808296
    15. Expression of CD79b is downregulated in both plasma cells and plasma cell myeloma. PMID: 21355953
    16. The B cell-specific B29 gene promoter is transactivated in B and non-B cells by cotransfection with the B cell-specific octamer cofactor gene, Bob1 (OCA-B/OBF-1). PMID: 11907094
    17. The alternative splicing variant DeltaCD79b may be a powerful modulator of BCR signaling that may play an important role in normal and malignant B cell PMID: 12384401
    18. Following B cell receptor cross-linking, a significant amount of the transgenic Ig beta pool (together with Ig alpha) remains on the B cell surface independent of surface immunoglobulin internalization. PMID: 15661909
    19. Results reveal tissue-specific patterns of chromatin structures and transcriptional controls at the CD79b/GH locus in B cells distinct from those in the pituitary gland and placenta. PMID: 16847312
    20. establish a strong linkage between Igbeta mRNA expression and somatic hypermutation in chronic lymphocytic leukaemia and highlight the complex relationships between biochemical parameters and clinical status in this disease PMID: 17315213
    21. Ig-beta was phosphorylated in about 20% of myeloma IgG BCR isolates, but not in normal B-cell controls. PMID: 17701175
    22. These results indicate that mutations in Igbeta can cause agammaglobulinemia in man. PMID: 17709424
    23. mutations responsible for agammaglobulinemia in humans PMID: 18978465

    顯示更多

    收起更多

  • 相關疾?。?/div>
    Agammaglobulinemia 6, autosomal recessive (AGM6)
  • 亞細胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 組織特異性：
    B-cells.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 1699

    OMIM: 147245

    KEGG: hsa:974

    STRING: 9606.ENSP00000376544

    UniGene: Hs.89575



×
生命科學計算平臺